Shares Magazine
$24.95-0.10 (-0.40%)31 Mar 2025, 19:14
Jump to:
Pfizer INC Fundamentals
| Company Name | Pfizer INC | Last Updated | 2025-03-31 |
|---|---|---|---|
| Industry | Drug Manufacturers - General | Sector | Healthcare |
| Shares in Issue | 5.671 bn | Market Cap | $141.50 bn |
| PE Ratio | 17.77 | Dividend per Share | $1.68 |
| Dividend Yield | 6.75 | Dividend Cover | 0.84 |
| EPS | $1.41 | EPS Growth (%) | 1.03 |
| PEG | 0.59 | DPS Growth (%) | 0.0244 |
| Debt Ratio | 0.2983 | Debt Equity Ratio | 0.6429 |
| Asset Equity Ratio | 2.4113 | Cash Equity Ratio | 0.2314 |
| Quick Ratio | 0.8200 | Current Ratio | 1.17 |
| Price To Book Value | 1.6044 | ROCE | 0 |
Pfizer INC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|---|---|---|---|---|
| Interim | 2025-01-24 | 2025-03-07 | USD | 0.4300 | |
| Prelim | 2024-11-08 | 2024-12-02 | USD | 0.4200 | |
| Interim | 2024-07-26 | 2024-09-03 | USD | 0.4200 | |
| Interim | 2024-05-09 | 2024-06-14 | USD | 0.4200 | |
| Interim | 2024-01-25 | 2024-03-01 | USD | 0.4200 | |
| Prelim | 2023-11-09 | 2023-12-04 | USD | 0.4100 | |
| Interim | 2023-07-27 | 2023-09-05 | USD | 0.4100 | |
| Interim | 2023-05-11 | 2023-06-09 | USD | 0.4100 | |
| Interim | 2023-01-26 | 2023-03-03 | USD | 0.4100 | |
| Prelim | 2022-11-03 | 2022-12-05 | USD | 0.4000 | |
| Interim | 2022-07-28 | 2022-09-06 | USD | 0.4000 | |
| Interim | 2022-05-12 | 2022-06-10 | USD | 0.4000 |
Pfizer INC Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|---|---|---|
| Tangible Assets | $18.39 bn | $18.94 bn | $16.27 bn |
| Intangible Assets | $123.94 bn | $132.68 bn | $94.75 bn |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | $163.04 bn | $183.17 bn | $145.94 bn |
| Stocks | $10.85 bn | $10.19 bn | $8.98 bn |
| Debtors | 0 | 0 | 0 |
| Cash & Equivalents | $20.48 bn | $12.69 bn | $22.73 bn |
| Other Assets | 0 | 0 | 0 |
| Total Assets | $213.40 bn | $226.50 bn | $197.21 bn |
| Liabilities | 2024 | 2023 | 2022 |
|---|---|---|---|
| Creditors within 1 year | $42.99 bn | $47.79 bn | $42.14 bn |
| Creditors after 1 year | $81.90 bn | $89.42 bn | $59.15 bn |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | $124.90 bn | $137.21 bn | $101.29 bn |
| Net assets | $88.50 bn | $89.29 bn | $95.92 bn |
| Equity | 2024 | 2023 | 2022 |
|---|---|---|---|
| Called up share capital | $480.00 m | $478.00 m | $476.00 m |
| Share Premium | $93.60 bn | $92.63 bn | $91.80 bn |
| Profit / Loss | $8.02 bn | $1.06 bn | $34.73 bn |
| Other Equity | $88.20 bn | $89.01 bn | $95.66 bn |
| Preference & Minorities | $294.00 m | $274.00 m | $256.00 m |
| Total Capital Employed | $88.50 bn | $89.29 bn | $95.92 bn |
| Ratios | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt Ratio | $0.39 | $0.40 | $0.25 |
| Debt-to-Equity | $0.64 | $0.68 | $0.33 |
| Assets / Equity | 2.4113 | 2.4113 | 2.4113 |
| Cash / Equity | 0.2314 | 0.2314 | 0.2314 |
| EPS | $2.16 | $1.06 | $6.24 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash from operating activities | $12.74 bn | $8.70 bn | $29.27 bn |
| Cashflow before financing | -$4.40 bn | $34.77 bn | $14.43 bn |
| Increase in Cash | -$1.81 bn | $2.45 bn | -$1.51 bn |
| Income | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | $63.63 bn | $59.55 bn | $101.17 bn |
| Cost of sales | $17.85 bn | $24.95 bn | $34.34 bn |
| Gross Profit | $45.78 bn | $34.60 bn | $66.83 bn |
| Operating Profit | 0 | 0 | 0 |
| Pre-Tax profit | $8.02 bn | $1.06 bn | $34.73 bn |
Pfizer INC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor. |
| Latest Interim Date | 30 Jul 2024 |
| Latest Fiscal Year End Date | 4 Feb 2025 |
Pfizer INC Directors
| Appointed | Name | Position |
|---|---|---|
| 2012-05-31 | Mr. Cavan M. Redmond | Group President |
| 2007-09-14 | Mr. Alan G. Levin | Senior Vice President |
| 2008-02-28 | Mr. Allen P. Waxman | Senior Vice President |
| 2005-02-24 | Charles L. Hardwick | Senior Vice President |
| 2009-04-30 | Dr. Corey S. Goodman,PhD | Senior Vice President |
| 2010-04-01 | Dr. Dana G. Mead | Director |
| 2025-03-04 | Mr. David M. Denton | Chief Financial Officer & EVP |
| 2014-04-24 | Ms. Constance J. Horner | Director |
| 2007-12-31 | Mr. David L. Shedlarz | Vice Chairman |
| 2017-04-27 | Dr. Frances D. Fergusson,PhD | Director |
| 2005-04-01 | Mr. Franklin D. Raines | Director |
| 2007-02-28 | Dr. Henry A. McKinnell,Jr,PhD | Director |
| 2010-12-15 | Mr. Jeffrey B. Kindler, Esq. | Director, Former Chairman & CEO |
| 2007-10-15 | Dr. John L. LaMattina, PhD | Senior Vice President |
| 2004-12-31 | John W. Mitchell | Senior Vice President |
| 2020-09-25 | Mr. James M. Kilts | Director |
| 2005-04-28 | Mr. Jean-Paul Valles | Director |
| 2020-02-28 | Ms. Loretta V. Cangialosi | Sr. Vice President, Controller |
| 2009-03-13 | Dr. Joseph M. Feczko, M.D. | Senior Vice President |
| 2025-03-04 | Ms. Lidia L. Fonseca | Executive Vice President |
| 2015-04-23 | Dr. Marc Tessier-Lavigne, PhD | Director |
| 2010-05-14 | Dr. Martin W. Mackay, PhD | Senior Vice President |
| 2010-12-15 | Ms. Mary S. Mcleod | Former Sr. Vice President |
| 2011-04-28 | Dr. Michael S. Brown, M.D. | Director |
| 2005-02-24 | Mr. Peter B. Corr | Senior Vice President |
| 2003-12-31 | Norton Robert W | Senior Vice President |
| 2025-03-04 | Ms. Sally Susman | Executive Vice President |
| 2010-04-22 | Mr. Robert N. Burt | Director |
| 2025-02-13 | Mr. Ronald E. Blaylock | Director |
| 2006-04-27 | Dr. Ruth J. Simmons | Director |
| 2024-12-31 | Mr. Shantanu Narayen | Director |
| 2006-12-29 | Ms. Sylvia Montero | Senior Vice President |
| 2010-03-31 | Mr. William R. Ringo, Jr | Senior Vice President |
| 2008-04-24 | Mr. William R. Howell | Director |
| 2005-02-24 | Ms. Yvonne R. Jackson | Senior VP - Human Resources |
| 2013-12-31 | Ms. Amy W. Schulman | Former Exec. Vice President |
| 2020-04-23 | Mr. Wyllie Don Cornwell | Director |
| 2011-04-01 | Mr. William C. Steere, Jr | Director |
| 2019-02-27 | Dr. Freda C. Lewis-Hall,M.D. | Executive Vice President |
| 2019-03-04 | Mr. Ian C. Read | Director, Executive Chairman |
| 2013-04-25 | Mr. William H Gray III | Director |
| 2015-02-25 | Mr. Geno J. Germano | Group President |
| 2014-04-24 | Mr. George A. Lorch | Director |
| 2011-03-31 | Mr. Natale S. Ricciardi | Senior Vice President |
| 2012-04-26 | Mr. John P. Mascotte | Director |
| 2024-04-25 | Ms. Suzanne Nora Johnson | Director |
| 2006-08-15 | Ms. Karen Katen | Vice Chairman |
| 2013-04-25 | Mr. M. Anthony Burns | Director |
| 2008-12-31 | Mr. Richard H. Bagger | Senior Vice President |
| 2006-04-27 | Dr. Stanley O. Ikenberry,PhD | Director |
| 2022-05-12 | Mr. William R. Carapezzi | Executive Vice President |
| 2018-03-29 | Mr. Stephen W Sanger | Director |
| 2024-10-30 | Dr. Scott Gottlieb,M.D. | Director |
| 2018-04-26 | Dr. Dennis A. Ausiello, M.D. | Director |
| 2022-02-26 | Mr. Frank A. D'Amelio | Executive Vice President |
| 2024-12-31 | Mr. James Robert Quincey | Director |
| 2024-04-25 | Dr. Susan J. Hockfield, PhD | Director |
| 2024-04-25 | Dr. Susan D. Desmond-Hellmann, M.D.,M.P.H. | Director |
| 2024-09-12 | Dr. G. Mikael Dolsten, M.D. | President R&D |
| 2025-03-04 | Mr. Douglas M. Lankler | Executive Vice President |
| 2012-10-31 | Ms. Kristin C. Peck | Executive Vice President |
| 2013-10-31 | Dr. Olivier Raymond Brandicourt, M.D. | Business Unit President |
| 2021-12-15 | Mr. John Douglas Young | Group President |
| 2024-12-31 | Mr. James C. Smith | Director |
| 2018-03-06 | Mr. Charles H. Hill | Executive Vice President |
| 2012-05-31 | Mr. David S. Simmons | Business Unit President |
| 2024-04-25 | Dr. Helen H. Hobbs, M.D. | Director |
| 2018-08-13 | Ms. Laurie J. Olson | Executive Vice President |
| 2016-12-31 | Mr. Anthony J. Maddaluna | Executive Vice President |
| 2024-12-31 | Mr. Rady A. Johnson | Executive Vice President |
| 2025-03-14 | Dr. Albert Bourla, D.V.M.,PhD | Director, Chairman & CEO |
| 2024-12-31 | Mr. Joseph J. Echevarria | Director |
| 2021-12-02 | Mr. Alexander R. Mackenzie | Executive Vice President |
| 2018-08-01 | Ms. Kirsten Lund-Jurgensen | Executive Vice President |
| 2023-05-10 | Ms. Angela Hwang | President, Global Biopharma |
| 2024-12-31 | Mr. Cyrus Taraporevala | Director |
| 2024-04-25 | Dr. Dan R. Littman, M.D.,PhD | Director |
| 2020-06-15 | Ms. Dawn Rogers | Executive Vice President |
| 2020-02-28 | Mr. Michael Goettler | Group President |
| 2025-02-27 | Ms. Jennifer B. Damico | SVP & Controller |
| 2025-03-04 | Ms. Payal Sahni | Executive Vice President |
| 2025-03-04 | Mr. Aamir Malik | Executive Vice President |
| 2025-03-04 | Mr. Michael McDermott | Executive Vice President |
| 2023-03-31 | Dr. William Pao, M.D.,PhD | Executive Vice President |
| 2025-03-04 | Dr. Chris Boshoff, M.D.,PhD | President, R&D |
| 2025-03-04 | Mr. Alexandre de Germay | Executive Vice President |
| 2025-03-04 | Dr. Andrew Baum, M.D. | Executive Vice President |
| 2024-10-10 | Mr. Mortimer J. Buckley | Director |
Pfizer INC Contact Details
| Company Name | Pfizer Inc |
|---|---|
| Address | 66 Hudson Boulevard East, New York, 10001-2192 |
| Telephone | +1 212 7334848 |
| Website | https://www.pfizer.com |
Pfizer INC Advisors
| Auditor | KPMG LLP |
|---|---|
| Phone | +1 212 758-9700 |
| Fax | +1 212 758-9819 |
| Auditor | KPMG Klynveld Peat Marwick Goerdeler SA |
|---|
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Aston Martin Lagonda Global Holdings PLC | 69.85 | 7.05 |
| British American Tobacco PLC | 3,182.00 | 1.86 |
| Moonpig Group PLC | 210.00 | 1.69 |
| Severn Trent PLC | 2,531.00 | 1.40 |
| Harbour Energy PLC | 210.30 | 1.40 |
| Imperial Brands PLC | 2,865.00 | 1.38 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Pets AT Home Group PLC | 216.40 | -8.46 |
| Molten Ventures PLC | 256.50 | -7.73 |
| Close Brothers Group PLC | 278.20 | -7.20 |
| International Consolidated Airlines Group S.A. | 260.80 | -6.62 |
| Raspberry Pi Holdings PLC | 466.60 | -6.27 |
| Mobico Group PLC | 58.15 | -6.06 |
Risers/fallers data from previous trading day. Today's data available from 8:15am.